* Q4 loss/shr $0.27, in line with estimates
* Q4 rev $44.1 mln vs. est $54.0 mln
* Sees 2010 rev $210 mln-$240 mln vs. est $209.1 mln
* Shares up 3 pct in premarket trade
March 9 Cancer drug developer Exelixis Inc
(EXEL.O) posted a quarterly loss in line with market
expectations, and forecast a full-year revenue above consensus
estimates, sending its shares up 3 percent in premarket trade.
The company, which said on Monday it would cut about 40
percent of its workforce and take related charges of about $15
million in the first quarter, sees 2010 revenue of $210 million
to $240 million and operating expenses of $280 million to $310
Analysts on average were expecting 2010 revenue of $209.1
million, according to Thomson Reuters I/B/E/S.
For the fourth quarter, the company posted a net loss of
$28.8 million, or 27 cents a share, compared with a loss of
$38.0 million, or 36 cents a share, in the year-ago period.
Revenue for the quarter was up almost 49 percent at $44.1
million, helped by increased license revenue from partners
Bristol-Myers Squibb (BMY.N) and Sanofi-Aventis (SASY.PA) on
Exelixis' experimental anti-cancer drugs.
Analysts on average expected the company to post a loss of
27 cents a share, on revenue of $54 million.
Shares of the company were up about 3 percent at $7 in
premarket trade Tuesday. They closed at $6.81 Monday on
(Reporting by Krishnakali Sengupta in Bangalore; Editing by
Ratul Ray Chaudhuri)